Literature DB >> 2541936

High uptake of RSU 1069 and its analogues melanotic melanomas.

J M Walling1, J Deacon, S Holliday, I J Stratford.   

Abstract

RSU 1069 and RSU 1164 are electron affinic agents that contain a nitro group together with a weakly basic alkylating aziridine moiety, and they represent lead compounds in the development of dual-function, bioreductive, hypoxic cell radiosensitizers. We studied the pharmacokinetics of these drugs in mice carrying KHT sarcoma. Lewis lung carcinoma, and B16 melanoma. Following an i.p. dose of 80 mg/kg, absorption was rapid and the elimination t1/2 was in the region of 30 min for both agents. Maximal tumour levels were 91, 16 and 19 microgram/ml for RSU 1069 and 109, 26 and 28 microgram/ml for RSU 1164 in. the B16, KHT and Lewis lung tumours, respectively. In B16 melanoma these levels corresponded to tumour:plasma ratios of 3.8 for RSU 1069 and 3.7 for RSU 1164. Cellular uptake of RSU 1069, RSU 1164 and a related compound, RB 7040, was measured in vitro as a function of extracellular pH. Melanotic cells from both B16 melanoma and HX118, a human tumour xenograft, showed substantially greater accumulation of these weakly basic sensitizers than any other cell type examined. Ratios of intra-:extracellular concentration (Ci/Ce) for RSU 1069 were around unity and independent of pH for Lewis lung cells and HX34 amelanotic melanoma cells, whereas ratios of up to 3 and 5 were obtained in B16 and HX118 cells, respectively. The highest measured value of Ci/Ce was 15 for RSU 1164 in HX118 cells at pH 8.4; this compares with a ratio of 1.5 for HX34 cells at the same pH. These studies indicate that the high levels of uptake of the weakly basic sensitizers into melanotic melanoma in vivo is a cell-mediated phenomenon and may be due to a lower average intracellular pH in the melanotic cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541936     DOI: 10.1007/BF00254101

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Stem-cell survival and tumor control in the Lewis lung carcinoma.

Authors:  G G Steel; K Adams
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

2.  Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma.

Authors:  S Dische
Journal:  Radiother Oncol       Date:  1987-10       Impact factor: 6.280

3.  A comparison of the tumour concentrations obtainable with misonidazole and Ro 03-8799.

Authors:  S Dische; M I Saunders; M H Bennett; E P Dunphy; C Des Rochers; M R Stratford; A I Minchinton; P Wardman
Journal:  Br J Radiol       Date:  1986-09       Impact factor: 3.039

4.  Primary radiotherapy of larynx and pharynx carcinoma--an analysis of some factors influencing local control and survival.

Authors:  J Overgaard; H S Hansen; K Jørgensen; M Hjelm Hansen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-04       Impact factor: 7.038

5.  Clonal variation in the sensitivity of B16 melanoma to m-AMSA.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer       Date:  1982-06       Impact factor: 7.640

6.  Studies on the mechanisms of the radiosensitizing and cytotoxic properties of RSU-1069 and its analogues.

Authors:  J M Walling; I J Stratford; G E Adams; A R Silver; I Ahmed; T C Jenkins; E M Fielden
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

7.  Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

8.  The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.

Authors:  M I Saunders; S Dische; D Fermont; A Bishop; I Lenox-Smith; J G Allen; S L Malcolm
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

9.  The differential cytotoxicity of RSU 1069: cell survival studies indicating interaction with DNA as a possible mode of action.

Authors:  I J Stratford; J M Walling; A R Silver
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

10.  Mechanism of action of some bioreducible 2-nitroimidazoles: comparison of in vitro cytotoxicity and ability to induce DNA strand breakage.

Authors:  P O'Neill; T C Jenkins; I J Stratford; A R Silver; I Ahmed; S S McNeil; E M Fielden; G E Adams
Journal:  Anticancer Drug Des       Date:  1987-04
View more
  6 in total

Review 1.  Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.

Authors:  Peter Wardman
Journal:  Br J Radiol       Date:  2018-03-20       Impact factor: 3.039

Review 2.  Hypoxia and drug resistance.

Authors:  B A Teicher
Journal:  Cancer Metastasis Rev       Date:  1994-06       Impact factor: 9.264

3.  Pharmacokinetics and cytotoxicity of RSU-1069 in subcutaneous 9L tumours under oxic and hypoxic conditions.

Authors:  K H Wong; C J Koch; C A Wallen; K T Wheeler
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

4.  Distribution of pimonidazole and RSU 1069 in tumour and normal tissues.

Authors:  L M Cobb; J Nolan; S A Butler
Journal:  Br J Cancer       Date:  1990-12       Impact factor: 7.640

5.  Bioreductive drugs and the selective induction of tumour hypoxia.

Authors:  J C Bremner; I J Stratford; J Bowler; G E Adams
Journal:  Br J Cancer       Date:  1990-05       Impact factor: 7.640

6.  Relationship between the melanin content of a human melanoma cell line and its radiosensitivity and uptake of pimonidazole.

Authors:  R el Gamoussi; M D Threadgill; M Prade; I J Stratford; M Guichard
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.